Meta-Analysis of Dropout in Treatments for Posttraumatic Stress Disorder

Zac E. Imel
University of Utah and VA Puget Sound Health Care System, Seattle, Washington

Matthew Jakupcak and Tracy L. Simpson
VA Puget Sound Health Care System, Seattle, Washington

Kevin Laska
Bedford VA Medical Center, Bedford, Massachusetts

Objective: Many patients drop out of treatments for posttraumatic stress disorder (PTSD); some clinicians believe that trauma-focused treatments increase dropout. Method: We conducted a meta-analysis of dropout among active treatments in clinical trials for PTSD (42 studies; 17 direct comparisons). Results: The average dropout rate was 18%, but it varied significantly across studies. Group modality and greater number of sessions, but not trauma focus, predicted increased dropout. When the meta-analysis was restricted to direct comparisons of active treatments, there were no differences in dropout. Differences in trauma focus between treatments in the same study did not predict dropout. However, trauma-focused treatments resulted in higher dropout compared with present-centered therapy (PCT), a treatment originally designed as a control but now listed as a research-supported intervention for PTSD. Conclusion: Dropout varies between active interventions for PTSD across studies, but variability is primarily driven by differences between studies. There do not appear to be systematic differences across active interventions when they are directly compared in the same study. The degree of clinical attention placed on the traumatic event does not appear to be a primary cause of dropout from active treatments. However, comparisons of PCT may be an exception to this general pattern, perhaps because of a restriction of variability in trauma focus among comparisons of active treatments. More research is needed comparing trauma-focused interventions to trauma-avoidant treatments such as PCT.

Keywords: PTSD, clinical trials, dropout, psychotherapy

Supplemental materials: http://dx.doi.org/10.1037/a0031474.supp

A number of effective psychotherapies are available for the treatment of posttraumatic stress disorder (PTSD; Society of Clinical Psychology, 2012). Approaches include treatments that focus on the traumatic event, such as prolonged exposure (PE), cognitive processing therapy (CPT), and eye movement desensitization and reprocessing (EMDR). There are also a variety of other interventions that do not place a primary focus on discussion of the trauma (see Foa, Keane, & Friedman, 2010, for examples). However, the average dropout rate across treatments in PTSD clinical trials is approximately 20% (Bradley, Greene, Russ, Dutra, & Westen, 2005; Hembree et al., 2003).

There are likely many factors that contribute to poor retention, but it is important to determine if psychotherapies differ in the extent to which they are tolerated. Patients may begin a treatment and find some aspect of it distressing or impractical, resulting in discontinuation. As discussed in several articles, there is ongoing debate regarding the belief that exposure-based treatments, which require the patient to retell traumatic events in detail to his or her therapist, are especially unacceptable or poorly tolerated by patients (e.g., Foa, Zoellner, Feeny, Hembree, & Alvarez-Conrad, 2002; Hembree et al., 2003; Speckens, Ehlers, Hackmann, & Clark, 2006; Tarrier et al., 1999). It remains important to determine if trauma-focused treatments result in higher dropout rates.

Dropout rates in clinical trials—the proportion of patients who begin but do not complete the full course of recommended treatment—are a common metric used to determine the tolerability of psychotherapies. A recent meta-analysis of dropout in treatments across psychological disorders found the average dropout rate was 19.7%, but this rate varied widely across studies (Swift & Green-
Similarly, dropout rates in PTSD clinical trials are notable for their variability. For example, the dropout rate for exposure-based treatments ranges from 0% (Neuner et al., 2008) to 41% (McDonagh et al., 2005), and the dropout rate for treatments that do not focus directly on the trauma memory is similarly wide ranging, from 0% (Schaal, Elbert, & Neuner, 2009) to 48% (Cotraux et al., 2008). Clearly, evidence in regard to differential dropout rates across psychotherapies for PTSD is mixed. As estimates of dropout rates from these individual clinical trials have limitations (e.g., could be due to sampling error, characteristics of the study or research team, number of sessions), a meta-analysis can provide a more robust estimate of differential dropout rates across interventions.

Three meta-analyses that have compared the dropout rates of treatment categories in PTSD (e.g., trauma-focused cognitive behavioral therapy [CBT]; EMDR; Bisson et al., 2007; Bradley et al., 2005; Hembree et al., 2003) were conducted. There was some evidence in the Bradley et al. (2005) meta-analysis that exposure-based treatments had higher dropout rates (e.g., exposure + cognitive therapy, 33%; CBT with no exposure, 17%), but no formal statistical tests were conducted. Generally, the authors of each meta-analysis concluded that the dropout rates of active treatment categories were comparable (active treatments being those that include specific ingredients purported to decrease PTSD symptoms; Powers, Halpern, Ferenschak, Gillihan, & Foa, 2010). However, two primary confounds may limit this conclusion such that the relative dropout rate of active treatments is unclear. These limitations are (a) dropout rates are compared across studies rather than directly within the same study, introducing the possibility that it is differences between studies that are captured rather than differences between treatments, and (b) active versus control and trauma-focused treatments are inappropriately classified.

**Direct Comparisons**

A limitation of both the Bradley et al. (2005) and the Hembree et al. (2003) meta-analyses is that the comparison of treatment categories was not restricted to treatments that were directly compared in the same study (i.e., effect sizes were not obtained from the direct comparison of two treatments in the same study). Studies vary with regard to participant demographics and clinical profiles (e.g., type of trauma, chronicity of PTSD), treatment standardization, study protocol and resources, treatment length, how dropout is defined, and other unmeasured variables (Shadish & Sweeney, 1991). These differences could influence estimates of dropout when specific treatments are compared with one another across studies. For example, the number of sessions involved in a similar treatment might vary across trials, with higher dropout in longer treatments (see Swift & Greenberg, 2012, for exploration of study-level covariates that influence dropout rates across disorders). In addition, a trauma-focused treatment might be offered in a group modality, wherein patients have less individual attention and may drop out at a higher frequency (see Schmurr et al., 2003). These differences could create the appearance of differences between approaches or obscure an actual effect.

To address the problems that may result from the comparison of dropout rates across studies, it is necessary to restrict analyses of dropout rate to the direct comparison of treatments in the same study. The use of direct comparisons eliminates the effect of between-study differences on estimates of relative dropout rates across treatment approaches: That is, the number of sessions and group versus individual modality are typically controlled in the same study. Bisson et al. (2007) conducted several meta-analyses of dropout in clinical trials that directly compared at least two of several treatment categories (k = 38). The authors reported that there were generally no differences in dropout between comparisons of active treatments, but concerns regarding the appropriate classification of treatments limit the conclusions of this and previous meta-analyses.

**Categorization**

A variety of psychotherapies are available for PTSD. As differences between approaches can be subtle, categorizing treatments entails difficult decisions about how treatments should be organized. Placing each treatment in a distinct category can introduce a variety of classification problems that may help explain why the relative tolerability of active treatments remains unclear. Three primary issues related to categorization are (a) analyzing treatments within the same category, (b) using catchall categories to classify control conditions and other treatments, and (c) determining a treatment’s focus on the trauma memory.

First, the general process of grouping treatments allows for tests of differences between categories, but it prevents an examination of differences in dropout within treatment categories (e.g., a CBT vs. a different CBT). Many published PTSD clinical trials are comparisons of treatments within a particular category (e.g., Arntz, Tiesema, & Kindt, 2007). However, all of the published meta-analyses are comparisons of different treatment categories and thus are not sensitive to potential differences between treatments within a category.

Second, it is difficult to categorize treatments that are not commonly tested in clinical trials (e.g., if there are few psychodynamic treatments, how should they be categorized?). This often forces researchers to use catchall categories (e.g., “other therapies”; Bisson et al., 2007; Bradley et al., 2005) for treatments that do not fit in primary categories. The treatments included in the catchall categories often differ in important ways from more commonly tested treatments (e.g., they are less trauma focused or non-CBT); thus, an adequate test of the relative dropout rate of treatments should accommodate these treatments. However, in the Bradley et al. (2005) meta-analysis, several treatments did not fit in the primary treatment categories (e.g., psychodynamic, hypnotherapy) and were excluded from comparisons of dropout.

Catchall categories can also result in the grouping of active treatments with interventions designed to be controls for active interventions (e.g., supportive therapy). Active interventions are typically defined as treatments that include therapeutic ingredients derived from a specific approach to psychotherapy purported to decrease PTSD symptoms (see Powers et al., 2010, p. 37), whereas control interventions (sometimes called nonspecific controls) are defined as those that are designed or altered to test some aspect of a comparison treatment (Mohr et al., 2009; Wampold et al., 1997). In the Hembree et al. (2003) meta-analysis, the control category had approximately half the dropout rate of most active treatment categories (e.g., 11.4% vs. 21%), but it included active treatments, interventions designed as controls, and waiting lists. In the Bisson et al. (2007) meta-analysis, the “other” treatment category had a
higher dropout rate than did some active treatments. However, the other category included both active treatments (hypnotherapy, psychodynamic) and controls (e.g., supportive therapies).

Alternatively, some treatments designed as controls have also been erroneously categorized. Specifically, Bisson et al. (2007) noted that the category of trauma-focused cognitive behavioral therapy had a higher dropout rate than did a treatment categorized as non-trauma-focused CBT. However, this treatment (present-centered therapy [PCT]—group; Schnurr, Friedman, Lavori, & Hsieh, 2001, Schnurr et al., 2003) was designed as a nonspecific control and excluded formal CBT components. As a further complication, PCT is now listed as an empirically supported treatment for PTSD with “strong research support,” along with other primary treatments for PTSD (e.g., PE; Chambless et al., 1998; Society of Clinical Psychology, 2012). In sum, the use of catchall categories prevents a full test of the relative dropout rate of active treatments and creates ambiguity in how the results of meta-analytic comparisons should be interpreted.

Finally, previous meta-analyses estimating the relative tolerability of PTSD treatments have classified treatments into dichotomous categories on the basis of the presence (trauma focused) or absence of a focus (non–trauma focused) on the traumatic event. A common definition used to classify treatments is based on the United Kingdom’s National Institute for Clinical Excellence Guidelines, which state, “the relevant consideration for the classification of [trauma focus] was whether or not the treatment mainly focused on the trauma memory and its meaning” (National Collaborating Centre for Mental Health, 2005, p. 54). However, important differences between the treatments may be included in trauma-focused and non-trauma-focused categories. In the Bisson et al. (2007) meta-analysis, some treatments were classified as trauma focused despite explicit provisions prohibiting the therapist from focusing on the trauma memory itself (e.g., Marks, Lovell, Noshirvani, Livanou, & Thrasher, 1998; Tarrier et al., 1999). Other treatments that may include direct discussion of traumatic events, such as psychodynamic treatment (Brom, Kleber, & Deffares, 1989), have been categorized in meta-analyses as non–trauma focused (Bisson et al., 2007; Hembree et al., 2003). A categorization scheme that allows for more variability in how the therapist deals with direct discussion of the trauma memory may provide a more sensitive test of dropout in clinical trials.

**Purpose and Hypotheses of the Present Meta-Analysis**

There is evidence that active interventions are similar in terms of dropout, but this evidence is limited by both the comparison of treatments across studies and various classification problems common in the meta-analysis of psychotherapies. Addressing these limitations may help resolve ongoing debates regarding the tolerability of PTSD treatments and provide clinicians and administrators with useful information when selecting among treatment options.

The purpose of the present meta-analysis is to provide a test of differences in dropout across all direct comparisons of active treatments for PTSD while addressing several limitations of previous categorization strategies. First, we statistically quantified the impact of between-study differences on dropout by examining variability in the proportion of dropout in each active intervention across studies. Second, we restricted the meta-analysis to direct comparisons of active treatment interventions and conducted an omnibus test that avoided any classification of treatments into specific categories, allowing comparisons of treatments both within and between categories. The omnibus test avoids confounds related to categorization noted above and tests whether there are any differences in dropout between active treatments that were directly compared in the same study.

Finally, we coded each intervention according to a graded level of trauma focus. Potential levels of trauma focus included (a) treatments that primarily focus on retelling the traumatic event, (b) treatments that do not focus on retelling but allow discussion of the trauma, and (c) treatments that refrain from any discussion of trauma. This categorization strategy provides a direct test of whether active treatments differ in the odds of dropout and allows for a more graded test of how trauma focus contributes to the tolerability of active treatments.

We expected that there would be differences in dropout rates in active treatment interventions across studies (Hypothesis 1). However, we expected there would be no differences between direct comparisons of active treatments (e.g., no differences between treatment interventions when controls were excluded; Hypothesis 2). Finally, we did not expect that differences in trauma focus between active treatments would predict dropout (Hypothesis 3).

**Method**

**Study Selection**

The literature search was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for meta-analysis (Moher, Liberati, Tetzlaff, & Altman, 2009; see Figure 1). To identify head-to-head comparisons of PTSD treatments, we performed a literature search of the major databases PubMed and PsycINFO using the keywords PTSD, post-traumatic stress disorder, psychotherapy, and treatment. In addition, we searched reference sections of previous meta-analyses of PTSD treatment and dropout, controlled studies of psychotherapy outcomes for PTSD, and literature reviews of PTSD treatment. The retrieval process was conducted between October 2009 and December 2010. To be included, the study had to have at least two psychological interventions to treat PTSD and an experimental design in which patients were randomly assigned. The experimental condition a patient was randomized to was considered an intervention if a patient received some treatment in the study context beyond a waiting list (e.g., referrals to usual care were excluded). Interventions paired with biological agents were excluded. Additionally, patients must have either met diagnostic criteria for PTSD using criteria from the Diagnostic and Statistical Manual of Mental Disorders (3rd or 4th ed.) or scored above traditional clinical cutoffs on standard measures of PTSD symptoms. However, there was not sufficient information across studies to code more specific diagnostic indicators (e.g., chronicity, number of traumatic events). Studies must have contained sufficient statistics to compute dropout rates. We used the authors’ definition of dropout, which was typically their report of the number of individuals randomized to a treatment condition that did not complete the full course (regardless of reason). In recent trials, numbers sufficient to cal-
dropout rates were typically reported in Figure 1 (e.g., Schnurr et al., 2007, p. 822). However, in older trials, it was often not possible to verify how rates were calculated. Zac E. Imel and Kevin Laska conducted the literature search, identifying study titles studies that potentially compared two interventions for PTSD. The results of the literature searches were merged in PubMed and the abstracts of studies were obtained and reviewed independently by Zac E. Imel and Kevin Laska. Zac E. Imel, Kevin Laska, and Matthew Jakcupcak independently evaluated full-text articles that appeared relevant to the current meta-analysis to determine if the study was a randomized clinical trial that compared at least two interventions for PTSD.

**Coding of Treatment Descriptions**

**Control versus active treatment.** We determined whether a treatment was intended to be an active or experimental psychological intervention by asking coders to use the treatment description to determine if the treatment was likely altered or designed as a control to test some aspect of a comparison treatment. Note that coding for control versus active treatment is problematic in component, parametric, or dismantling studies wherein the amount or presence of a specific treatment component is added or removed and then compared with the original (e.g., PE vs. PE + cognitive restructuring; Foa et al., 2005), typically to test a specific component of the reference treatment. Here, an active
intervention (e.g., PE) effectively serves as a control for another experimental condition. We excluded studies from control versus active treatment coding that were purely component, parametric, or dismantling studies (e.g., CPT vs. CPT—cognitive only vs. writing assignment; Resick et al., 2008). Accordingly, tested treatments that exclusively used this design were not included in primary analyses.

**Trauma focus.** We divided treatments into three categories: (a) trauma specific, (b) trauma inclusive or neutral, and (c) trauma avoidant. Trauma-specific treatments included explicit retellings of the trauma memory (e.g., PE; Foa et al., 1999). Trauma-inclusive or -neutral treatments did not specify retellings of the trauma memory but may have allowed discussion of the meaning or memory of the trauma (e.g., psychodynamic; Brom et al., 1989). Finally, trauma-avoidant treatments did not include retelling or focus on the trauma memory or its meaning (e.g., supportive counseling; Foa, Rothbaum, Riggs, & Murdock, 1991). Scores ranged from 1 to 3, with higher scores indicating more trauma focus.

**Coding process.** First, each author coded an initial set of 10 treatment descriptions. We then discussed disagreements and arrived at a consensus for each condition. Second, we trained two doctoral students to serve as masked raters. The masked raters independently evaluated the same 10 treatment descriptions (note that all other details of the study had been removed). To establish 100% agreement with the initial coding decisions made by the authors, Zac E. Imel then met with the raters to address errors and to discuss and resolve any disagreements among the raters. Raters then independently coded each treatment condition for degree of trauma focus and active versus control treatment. Interrater agreement was high for the rating of trauma focus (intraclass correlation = .91, but somewhat lower for the coding of control condition, intraclass correlation = .73). Zac E. Imel then discussed each disagreement with the raters. All disagreements were resolved after discussion. Note that one additional study was identified after the conclusion of the retrieval and initial coding process (Gilboa-Schechtman et al., 2010) and thus was not included in reliability analyses. Zac E. Imel and Kevin Laska coded the treatment descriptions. We agreed on both trauma focus and control ratings.

**Statistical Analysis**

To test Hypothesis 1 in regard to the effect of between study differences in dropout from active treatments, we determined the proportion of patients that dropped out across active interventions in each study. This analysis provided an estimate of the overall dropout rate and its variability across active interventions. We also examined trauma focus, group versus individual modality, and number of sessions as predictors of differences in dropout (b) across treatments.

As a test of Hypothesis 2, we examined differences in dropout between active treatments that were directly compared in the same study. Instead of deriving a proportional estimate of dropout for each treatment, differences in dropout for each active treatment comparison were calculated as a log odds ratio (LOR) with numbers greater than zero indicating greater odds of a patient dropping out of the reference treatment. Because this analysis contained a variety of treatment types (e.g., EMDR, stress inoculation therapy, hypnosis, psychodynamic, CR), the reference treatment is arbitrary. To provide an omnibus test of within-study differences in dropout across treatments that were directly compared, we used an approach wherein the direction of the effect size was randomly assigned (see Wampold et al., 1997). Randomization forces the average LOR to be close to zero (as necessarily half of the effect sizes will be above zero and half below) and so the test of differences in dropout among active treatments is provided by the test of heterogeneity. A large heterogeneity estimate ($I^2$) would be inconsistent with Hypothesis 2, suggesting some active treatments result in larger dropout rates compared with others. A nonsignificant heterogeneity estimate would be consistent with Hypothesis 2, suggesting that direct comparisons of treatments consistently result in little difference in dropout. We also included a sensitivity analysis to determine if excluding component studies biased the meta-analysis of active treatments. Specifically, the excluded comparisons were integrated with comparisons of active treatments, and we examined heterogeneity in a similar manner.

To determine the effect of differences in trauma focus on dropout from active treatments (Hypothesis 3), we calculated the imbalance in trauma focus among active treatments that were directly compared and entered it as a predictor of the LOR of dropout in a metaregression. The indicator of imbalance of trauma focus ranged from −2 to 2, wherein a positive score indicated that the first treatment was more trauma focused and a negative score indicated that the second treatment was more trauma focused. A positive relationship between this variable and the odds of dropout would indicate that as the relative trauma focus of the first treatment increased, the odds of dropping out of the first treatment compared with the second increased. Note that restricting analyses to direct comparisons eliminated most variability in number of sessions and group versus individual treatment (e.g., most treatments directly compared were of the same length). Accordingly, these variables were not examined as predictors of dropout. Finally, we conducted several additional sensitivity analyses to determine if the omnibus test of trauma focus was missing more subtle differences in dropout. These included direct comparisons of (a) PE to other treatments; (b) treatments rated as trauma specific to treatments rated as trauma neutral or avoidant; and (c) trauma-specific treatments and PCT, a treatment originally designed as a control that recently was listed as a research-supported psychological treatment for PTSD that has “strong research support” (Society of Clinical Psychology, 2012). PCT was found to be equivalent to established treatments in at least two between-group trials (Chambless et al., 1998). For ease of interpretation, we converted certain LOR effect sizes to standard odds ratios.

We used random effects meta-analytic procedures that assume the $k$ comparisons included in the meta-analysis are a random selection of comparisons drawn from the population. Consequently, results from random effects models can be generalized to this hypothetical population rather than limited to the observed studies in the meta-analysis (Cooper, Hedges, & Valentine, 2009). Primary analyses were conducted in R (R Core Development Team, 2011) with the meta-analysis package metafor (Viechtbauer, 2010).

Note that in small samples, it is not uncommon for zero patients to drop out of a given treatment. Accordingly, odds ratios cannot be directly calculated and will have nonpositive sampling variances. This is problematic for meta-analytic aggregation procedures, as the weight of a study with a nonposi-
tive sampling variance is 1/0 (Viechtbauer, 2010). Our solution was to add .5 to all cells in the effect size calculation (Cooper et al., 2009).

Results

Forty-two studies included the direct comparison of at least two interventions. Seventeen comparisons were coded as comparisons of at least two active treatments, pulled from a total of 54 treatments coded as active interventions. Seventeen treatments were component conditions (e.g., CPT–cognitive only vs. CPT) and thus were not coded as either active or control. The range of trauma focus was restricted among active interventions: 41 (76%) were coded trauma specific, 10 (19%) were coded trauma neutral, and only three (6%) were coded trauma avoidant. Of the control interventions that were excluded, none (0%) were coded trauma specific, four (16%) were coded trauma neutral, and 21 (84%) were coded trauma avoidant. The correlation between being rated a control intervention and greater trauma focus was extremely large \( r = .81 \). Across active treatments, the number of sessions ranged from four (Neuner, Schauer, Klaschik, Karunakara, & Elbert, 2004) to 30 (Schnurr et al., 2003), \( M = 10.96, SD = 5.26 \). The supplemental materials provide additional detail on all studies.

The aggregate proportion of dropout across all 54 active treatment arms (1,850 patients; \( M = 34.26, Mdn = 23.5 \)) was 18.28%, 95% confidence interval (CI) [14.84%, 21.75%]. Consistent with Hypothesis 1, heterogeneity between active interventions across studies was very large, \( F^2 = 78.40\%, Q(53) = 310.29, p < .0001 \), suggesting that dropout rates varied quite dramatically across studies. As an additional exploratory test, we eliminated within-study variability and then reexamined variability in dropout rates across studies (i.e., the number of completions and dropouts was summed across each active intervention in a study, resulting in a study-level dropout rate). There was no reduction in the previous variability estimate, \( F^2 = 89.40\%, Q(35) = 311.76, p < .0001 \), suggesting that variability in dropout rate across studies is large and within-study variability did not contribute to variability estimates. An increase in trauma focus did not predict an increase the dropout rate, \( b = -0.003, 95\% CI [-0.06, 5\%] \). However, group treatment was associated with a 12% increase in dropout rate, \( b = 0.12, p = .009, 95\% CI [3\%, 21\%] \). Number of sessions was also associated with an increase in the dropout rate, \( b = 0.01, p = .009, 95\% CI [0.3\%, 1.5\%] \), meaning that one additional session was associated with an addition of one percentage point to the predicted dropout rate.

The rank correlation test (Begg & Mazumdar, 1994) indicated a significant correlation between the proportion of dropout and sampling variance, \( r = .28, p < .003 \), indicating that smaller studies tended to have a higher proportion of patients dropping out of active treatment.

Next, we examined the LOR of dropout in the 17 comparisons of active treatments (i.e., a comparison in which neither treatment was coded as a control). We randomly assigned \(+/-\) positive and negative signs to the effect size for each comparison; thus, the aggregate odds of dropout across comparisons was close to zero, LOR = .05, 95% CI [−.31, .40]. Consistent with Hypothesis 2, among direct comparisons of active treatments, there was no evidence of variability in the LOR of dropout across studies, \( P^2 = 0.00\%, Q(16) = 8.17, p > .50 \) (see Figure 2). We also conducted a sensitivity analysis wherein the above model was fit repeatedly with a different effect size removed. This test involved 17 meta-analyses, each with a different comparison left out of the model (Viechtbauer & Cheung, 2010). Results were consistent with the primary analysis.

We tested the possibility that excluding comparisons of component and dismantling treatments (21 comparisons) from the analysis of active comparisons was responsible for the lack of differences between active treatments. To do so, we combined the component and dismantling comparisons with the set of active treatment comparisons (for a total of 38 comparisons). The homogeneity estimate was unchanged, \( F^2 = 0.00\%, Q(37) = 36.97, p = .47 \), indicating that dropout among active treatments was not biased by the exclusion of component and dismantling studies.

Consistent with Hypothesis 3, the effect of differences in trauma focus between comparisons of active treatments was not significant, LOR = 0.21, \( p = .43, 95\% CI [-0.32, 0.74] \), indicating that more trauma-focused treatments were not associated with an increase in the odds of dropout in the context of comparisons with other active treatments. We conducted additional tests to rule out the potential that this general analysis of trauma focus across active treatments was missing more subtle differences in dropout. First, we examined if the prototypical trauma-specific treatment, PE, had higher dropout rates than other active treatments did (\( k = 7 \)). Also consistent with Hypothesis 3, there was no difference in LOR of dropout between PE and other active treatments, LOR = −0.05, \( p > .50, 95\% CI [-0.52, 0.62] \), \( F^2 = 0.00\%, Q(6) = 3.86, p > .50 \). A limitation of this finding is that many of the active treatments with which PE was compared were also rated trauma specific (e.g., EMDR). We also compared active treatments that were rated trauma specific with those treatments that were rated trauma neutral or avoidant (\( k = 9 \)). Similarly, there was no difference in dropout between trauma-specific and trauma-neutral or -avoidant treatments, LOR = 0.27, \( p > .50, 95\% CI [-0.34, 0.81] \), \( F^2 = 0.00\%, Q(8) = 2.46, p > .50 \).

Finally, we tested the effect of including comparisons of trauma-specific treatments and PCT, a trauma-avoidant control that was recently labeled a psychological treatment with strong research support, in the original set of 17 active treatment comparisons. We combined the PCT comparisons with the original set of 17 active treatment comparisons (\( k = 20 \)) and examined variability in effects in a manner similar to Hypothesis 2 above. The estimate of between-study variability increased, \( F^2 = 32.34\%, Q(19) = 26.81, p = .11 \), but was not significant. However, because this may indicate that including PCT comparisons (that were all comparisons of trauma-specific vs. trauma-avoidant treatments) increased variability in dropout among treatments comparisons, we then used metaregression to examine the effect of differences in trauma focus among this set of 20 comparisons. Inconsistent with Hypothesis 3, the effect of trauma focus was significant, LOR = 0.33, \( p < .0001, 95\% CI [0.16, 0.49] \), indicating that trauma-focused treatments were associated with an increase in the odds of dropout when PCT comparisons were included.

To further explore this finding, we examined the difference in the odds of dropout among the three comparisons of trauma-specific interventions and PCT. There was a significant difference in the odds of dropout between trauma specific treatment and PCT, LOR = 0.70, \( p = .0009, 95\% CI [0.29, 1.11] \), \( F^2 = 22.15\%, Q(2) = 3.54, p = .17 \). The LOR converts to an odds ratio of 2.02,
which suggests trauma-specific treatment was associated with a twofold increase in the odds of dropout compared with PCT. Specifically, 36% of patients dropped out of trauma-specific treatment compared with 22% of patients who received PCT, a difference of 14%.

**Discussion**

The current meta-analysis provides a rigorous test of the relative tendency of patients to dropout of PTSD treatments in clinical trials. It provides several methodological contributions. We used a coding system that separated active and control treatments while being sensitive to the range of variability in trauma focus across PTSD treatments (i.e., trauma specific, neutral, and avoidant). In addition, we quantified the amount of between-study variability in dropout and then restricted the examination of treatment differences to direct comparisons of active PTSD treatments, removing any bias contributed by between study differences. Finally, in contrast to previous meta-analyses, our approach was sensitive to potential differences in dropout both within and between treatment categories.

We found a large amount of variability in dropout among active interventions across studies. In addition, several study-level variables, including group modality and number of sessions, were associated with dropout. However, restricting the analysis of dropout to direct comparisons of active treatments reduced variability between studies to zero. Consistent with general claims from previous meta-analyses (Bisson et al., 2007; Hembree et al., 2003; Swift & Greenberg, 2012), there was no evidence of differences in dropout between these active treatments.

Findings in regard to the effect of trauma focus were mixed. Differences in trauma focus did not predict dropout across studies. There were also no differences in dropout in direct comparisons of PE to other active interventions as well as the more general comparison of treatments that were...
rated trauma specific to those that were not. However, only three treatments in the 17 comparisons of active interventions were trauma avoidant. It appears the de facto way to design a control intervention in PTSD intervention research is to remove discussion of the trauma memory. Given that many CBTs focus on emotional processing through exposure to the trauma memory as a primary therapeutic ingredient, this is not surprising. However, one possibility is that the restriction of range in trauma focus among active treatments may obscure a real effect of trauma focus on dropout. Consistent with this idea, comparisons of PCT (a trauma-avoidant control) and trauma-specific treatments appear to be an exception to the pattern of no effect of trauma focus on dropout. There was evidence across three relatively large trials (695 patients in total) that dropout is lower in PCT compared with trauma-specific treatments. This evidence stands in contrast to prior meta-analyses that provided little evidence of differences in dropout between trauma and non-trauma-focused treatments (e.g., Bisson et al., 2007; Hembree et al., 2003).

Limitations

This meta-analysis has several limitations. First, although group modality and number of sessions predicted dropout across studies, a lack of within-study comparisons that varied on these parameters (e.g., group vs. individual in the same study) means these results could not be tested in the meta-analysis of direct comparisons. Second, the meaning of dropout in clinical trials is not clear. It is possible that some patients who do not complete treatment have outcomes that are comparable to those who do. There is evidence that much of the improvement in psychotherapy happens early in treatment. For example, patients who receive the fewest sessions of psychotherapy in community settings often improve the most (Baldwin, Berkeljon, Atkins, Olsen, & Nielsen, 2009). In this sense, some dropouts may actually be better characterized as early completers. Specific groups of PTSD patients (e.g., patients with one recent focal trauma vs. prolonged and repeated traumatic experiences) who drop out of PTSD treatment may contain as many successes as failures. This apples-and-oranges problem may obscure potential differences between treatments. Researchers conducting outcome studies should consider reporting both the number of patients that did not complete the full course of treatment and their symptom severity at termination (Hembree et al., 2003).

Perhaps most important, conclusions regarding dropout among active interventions should be restricted to the types of interventions included in the meta-analysis (primarily trauma specific and neutral). There was some diversity among active interventions that were directly compared in this meta-analysis, but comparisons were primarily of trauma-specific and neutral (repeated discussions of the trauma memory are not required but may be allowed) interventions. Increasing the number of trials with emerging therapies for PTSD (Schnyder, 2005) that do not include a focus on the trauma memory, such as IPT (Markowitz, 2010; Rafaeli & Markowitz, 2011), behavioral activation (Jakupcak et al., 2006), acceptance and commitment therapy and mindfulness-based approaches (Walser & Westrup, 2007), and now PCT, may provide a more thorough test of whether treatments with varying degree of focus on trauma differ in their ability to retain patients.

A final factor that is germane to the issue of dropout that has not yet been incorporated into PTSD trials or meta-analytic work is the importance of the therapist providing the treatment. There is initial evidence that therapists differ in the rate at which patients drop out of treatment (Owen, Imel, & Adelson, 2012). A failure to model potential therapist differences in dropout may bias traditional statistical tests used to make treatment comparisons and inflate the size of effects attributed to treatments (Kenny & Judd, 1986; Wampold & Serlin, 2000). As therapist differences were not modeled in any of the trials included in this (or any other) meta-analysis, it is possible that results represent an overestimate of the true differences in dropout between treatments. A direction for future research would be to investigate therapists as a source of dropout and also the characteristics of those therapists who routinely retain patients in treatment.

Clinical Implications

Many have been concerned that exposure-based therapies can lead to symptom exacerbation and result in dropout (McFarlane & Yehuda, 2000). Our findings suggest that dropout rates are not significantly different among active treatments. Accordingly, if administrators or clinicians are choosing among a menu of these treatment options, which primarily include trauma specific and neutral interventions, there is no compelling reason to expect any active treatment will enhance retention compared with any other. The implications of lower rates of dropout from PCT compared with trauma-specific active treatments are more complex. This finding could be dismissed because PCT was designed as a control treatment. The comparability of an active treatment that demands the commitment and involvement of the patient with a sham that was designed to prevent overlap with a comparison is subject to numerous confounds. In addition, therapists would seem unlikely to offer a control intervention wherein they are prevented from ever asking about the traumatic event and redirect the patient to other topics if the patient initiates such a discussion. Similarly, administrators would not likely be interested in the dissemination of a control treatment. However, PCT appears to differ from other psychological controls in important ways. Many psychological controls contain little beyond active listening and the proscription of specific therapist activities (Mohr et al., 2009). PCT is more developed, with a cogent rationale, training, treatments manuals, and explicit psychological bases of the treatment (e.g., McDonagh et al., 2005). Moreover, PCT was of comparable efficacy to established treatments in three clinical trials such that it was recently included in a list of empirically supported treatments for PTSD (Society of Clinical Psychology, 2012).

Despite the advantage of PCT, the effect is dwarfed by problems with retention in real-world studies of treatment utilization. Only 56% of PTSD patients who received some treatment in the community received a minimally adequate dose of psychotherapy (defined as at least eight 30-min sessions; Wang et al., 2005). Accordingly, the dropout rate of 18% in clinical trials would represent a massive improvement. Thus, the most promising method for improving retention in the community is not likely tied to a specific treatment approach, but it may involve systemic and logistical changes. Thus, retention might be improved by focusing on disseminating the machinery of clinical trial management that can be replicated so that community settings can approach the
ability of clinical trials to retain patients. This might include therapist training, support, and supervision; patient screening; regular assessment; and ongoing contact with assistants that may promote session attendance.

In conclusion, dropout rates varied widely across studies, suggesting that attempts to compare the dropout rates of active interventions across studies should be interpreted with caution. It is more appropriate to interpret a dropout rate as an indicator of something about the study itself rather than an indication of a given treatment’s tolerability. Meta-analytic conclusions about specific PTSD treatments should be restricted to treatments compared in the same study, which control for study level confounds. Here, evidence regarding dropout among active treatments mirrors the comparative efficacy of active treatments (Benish, Imel, & Wampold, 2008; Powers et al., 2010): There is little evidence that some active treatments result in higher dropout rates compared with other treatments. However, PCT may be an exception to this general pattern of no differences among active treatments, perhaps because of a restriction of range in trauma focus among evaluated treatments. If future research replicates this pattern of comparative efficacy and a lower rate of dropout relative to other treatment modalities, it would seem appropriate to consider PCT a first line treatment, especially for patients who do not prefer a trauma-focused treatment.

References

References marked with an asterisk indicate studies included in the meta-analysis.


Received April 27, 2012
Revision received November 19, 2012
Accepted November 19, 2012